4 Dependable Dividend-Paying Singapore Stocks for Your CPF Investment Account
Singapore's Central Provident Fund (CPF) system is a great way to save consistently and grow your retirement funds.
The good news is that the CPF Ordinary Account (OA) offers you the option to invest your CPF monies to enjoy even better returns through the CPF Investment Account (CPFIA).
You can use your CPFIA to invest in a wide range of Singapore stocks and REITs.
For such investments, the company in question must possess strong characteristics such as a robust business model, a consistent dividend track record and steady earnings growth.
Here are four reliable Singapore stocks that you can consider for your CPFIA.
Haw Par is a conglomerate with four key divisions – healthcare, leisure, property, and investments.
Its healthcare division owns the famous Tiger Balm brand which manufactures and distributes ointments, salves, and pain patches.
The group reported a commendable set of earnings for 2024.
Revenue rose 5.5% year on year to S$244.8 million although gross profit dipped slightly by 0.6% year on year to S$134.1 million.
Net profit came in at S$228.3 million, up 5.4% year on year.
The business also generated a positive free cash flow of S$50.3 million and received a total of S$149.1 million in dividend income, a step up from the S$136.2 million received in 2023.
A final dividend of S$0.20 was declared, unchanged from a year ago.
In addition, Haw Par also declared a special dividend of S$1 per share, taking the total dividend for 2024 to S$1.40 per share (inclusive of a S$0.20 interim dividend).
The conglomerate has a long, storied history of paying out increasing dividends and this special dividend is akin to extra icing on the cake.
Sheng Siong is one of the largest supermarket chains in Singapore with 77 outlets across the island.
The retailer sells a wide variety of products including live, and chilled produce along with toiletries, general merchandise, and daily necessities.
Sheng Siong demonstrated steady store growth since 2020 when the pandemic broke out, with its store count increasing from 63 to 77 today.
2024 saw continued growth in the retailer's top and bottom lines.
Revenue rose 4.5% year on year to S$1.4 billion while operating profit inched up 2.7% year on year to S$159.7 million.
Net profit increased by 2.6% year on year to S$137.5 million.
The supermarket operator's free cash flow jumped 20.3% year on year to S$200.8 million.
Sheng Siong paid out a total dividend of S$0.064, a step up from the S$0.0625 paid for 2023.
The group intends to open at least three new stores per year and for 2024, it doubled this target by opening six new stores.
Management is waiting for the results of the tender for eight additional stores to be released which could see the retailer opening more stores this year in addition to the two that opened in the first two months of 2025.
CapitaLand Integrated Commercial Trust, or CICT, is a retail and commercial REIT with a portfolio of 21 properties in Singapore, two properties in Germany, and three properties in Australia.
The REIT had assets under management (AUM) of S$26 billion as of 31 December 2024.
CICT reported a commendable performance despite the presence of headwinds such as high interest rates and persistent inflation.
For 2024, gross revenue edged up 1.7% year on year to S$1.6 billion while net property income improved by 3.4% year on year to S$1.15 billion.
Distribution per unit (DPU) crept up 1.2% year on year to S$0.1088.
Apart from a resilient financial performance, CICT also displayed solid operating metrics.
The portfolio's committed occupancy stood at 96.7% while rental reversion came in positive at 8.8% and 11.1% for the REIT's retail and office divisions, respectively.
The REIT has two asset enhancement initiatives (AEIs) slated for completion in the second half of this year and should see a full-year contribution from the acquisition of ION Orchard Mall.
Parkway Life REIT, or PLife REIT, is a healthcare REIT with a portfolio of 75 properties – three in Singapore, 60 in Japan, 11 in France, and one in Malaysia.
Its total AUM stood at around S$2.46 billion as of 31 December 2024.
PLife REIT reported a mixed set of earnings for 2024.
Gross revenue and NPI dipped by 1.5% and 1.8% year on year, respectively, to S$145.3 million and S$136.6 million.
However, DPU stood at S$0.1492, up 1% year on year.
The healthcare REIT maintained a moderate gearing level of 34.8% and had a very low cost of debt of just 1.48%.
The REIT has also hedged 87% of its interest rate exposure to mitigate further rises in its finance costs.
PLife REIT has an enviable of uninterrupted increases in its core DPU since its IPO back in 2007.
Close to 91% of its leases (by gross revenue) also have downside protection.
Just 2% of the REIT's loans are due for refinancing this year.
Want to protect your child's money from inflation? Transform your child's 'piggy bank' into a 'golden goose' that keeps giving even until they have grandchildren. Our latest FREE report shows you a stress-free method and 3 superstar stocks that could protect your child's money from inflation. Click HERE to get a copy of our latest guide.
Follow us on Facebook and Telegram for the latest investing news and analyses!
Disclosure: Royston Yang does not own shares in any of the companies mentioned.
The post 4 Dependable Dividend-Paying Singapore Stocks for Your CPF Investment Account appeared first on The Smart Investor.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27-05-2025
- Yahoo
Sheng Siong Group's (SGX:OV8) investors will be pleased with their 25% return over the last year
If you want to compound wealth in the stock market, you can do so by buying an index fund. But investors can boost returns by picking market-beating companies to own shares in. For example, the Sheng Siong Group Ltd (SGX:OV8) share price is up 20% in the last 1 year, clearly besting the market return of around 14% (not including dividends). So that should have shareholders smiling. Longer term, the stock is up 20% in three years. So let's assess the underlying fundamentals over the last 1 year and see if they've moved in lock-step with shareholder returns. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). Sheng Siong Group was able to grow EPS by 2.9% in the last twelve months. This EPS growth is significantly lower than the 20% increase in the share price. So it's fair to assume the market has a higher opinion of the business than it a year ago. You can see below how EPS has changed over time (discover the exact values by clicking on the image). Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here. When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. In the case of Sheng Siong Group, it has a TSR of 25% for the last 1 year. That exceeds its share price return that we previously mentioned. And there's no prize for guessing that the dividend payments largely explain the divergence! It's nice to see that Sheng Siong Group shareholders have received a total shareholder return of 25% over the last year. Of course, that includes the dividend. That gain is better than the annual TSR over five years, which is 8%. Therefore it seems like sentiment around the company has been positive lately. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for Sheng Siong Group you should know about. If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Singaporean exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
27-05-2025
- Yahoo
PA making state government workforce stronger and more competitive
May 26—WILKES-BARRE — To mark the one year anniversary of Gov, Josh Shapiro's executive order to strengthen the Commonwealth state employee workforce, the Shapiro Administration this week announced the completion of key milestones to improve recruitment, hiring, retention, and development so that Commonwealth agencies can continue to attract highly qualified and dedicated public servants to address the needs of Pennsylvanians. Initiatives to hire more bilingual workers, expand access to childcare, and engage with job seekers are delivering real results that build on Gov. Shapiro's goal of making the Commonwealth a top employer. "Pennsylvania state government should be a place where the best and brightest want to work; a place where every Pennsylvanian, no matter their background, can see themselves thriving in meaningful careers," said Secretary of Administration Neil Weaver. "Through the work of the HIRE Committee and the actions taken through the Governor's executive order, we are making tangible progress in creating a workforce that is as diverse, dynamic, and innovative as the people we serve." "At DGS, we're proud to play a key role in supporting Governor Shapiro's vision of making the Commonwealth a top-tier employer by investing in the people who serve Pennsylvania every day," said Secretary of General Services Reggie McNeil. "From expanding access to quality childcare to improving physical accessibility and ensuring dignity through free menstrual products and single-use restrooms, our work is focused on creating a workplace that values every employee and meets the needs of a modern workforce." Over the past year, the HIRE Committee has built on this foundation through targeted initiatives and pilot programs that include: —Eliminating Waiting Periods for Benefits — Effective Aug. 1, 2025, the waiting period for new hires to enroll dependents into PEBTF medical, prescription drug, dental, and vision coverage without paying additional out of pocket costs will be eliminated. —Offering Financial Incentives for Bilingual Employees — Launched in April, this pilot program at L&I provides a $1.00 per hour bonus — almost $1,000 more over the course of the 6-month pilot — for bilingual employees in certain Unemployment Compensation and PA CareerLink positions to ensure Pennsylvanians who speak a language other than English receive efficient, effective service. —Fostering Re-entrant Success through Employment Opportunities — OA is piloting a hiring program with the Department of Corrections to promote pathways to employment in state government for people who have previously interacted with the criminal justice system. —Hosting the Second Annual Commonwealth Job Fair — OA hosted the second multi-agency job fair for job seekers in the Harrisburg area in March, attracting over 1,000 registrants to learn about open positions and opportunities to join public service. —Enhancing Services for Pennsylvanians with Limited English Proficiency — After hiring the first enterprise language access program manager, OA has prioritized expanding technical assistance and training for agency staff on procuring high-quality translations and language services, supporting agencies as they develop language access plans, and building open and continuous communication with agencies to distribute translated materials and information to Pennsylvanians who need it most. —Promoting Employee Work/Life Balance — The Commonwealth has expanded assistance for mental health and substance misuse issues, family care-giving, and more to support the well-being of all employees. —Expanding Access to Employee Child Care — DGS is managing the expansion of the Keystone Early Learning Center, a year-round childcare facility available to Commonwealth employees. —Improving Accessibility of Commonwealth Buildings — DGS continues to lead an accessibility study that is the first step in helping to improve access and inclusivity for individuals with disabilities throughout the Pennsylvania Capitol Complex. —Offering Free Menstrual Products — DGS has placed menstrual products in woman's restrooms and single-use restrooms throughout Commonwealth buildings directly managed by the agency to ensure that essential hygiene products are readily available to employees and visitors who need them. —Continuing to Add Single-Use Restrooms — DGS has added 12 single-use restrooms in state government facilities following the issuance of the HIRE executive order. State graduates inaugural class of 15 small business owners from Mentor Protégé Program The Pennsylvania Department of General Services (DGS) this week graduated the inaugural cohort of the Mentor Protégé Program (MPP) — a key initiative started under the Shapiro-Davis Administration to expand opportunities and access for small, small diverse, and veteran-owned businesses seeking to compete in the Commonwealth's procurement process. The MPP, established under Governor Shapiro's Executive Order 2023-18, provides small business owners with one-on-one mentoring relationships with seasoned prime contractors. Mentors provide guidance, support, and valuable insights to help protégés improve their business management and contract bidding skills which could be useful in acquiring additional Commonwealth business. "This program is a reflection of the Shapiro-Davis Administration's commitment to economic equity and opportunity," said DGS Secretary Reggie McNeil. "By investing in mentorship and creating space for small, small diverse and veteran-owned businesses to grow, we're strengthening Pennsylvania's economy and seeking to ensure that our procurement processes reflect the diversity and talent of our business community." This first cohort, focused on IT services, included 15 business participants who engaged in targeted programming on business development, procurement readiness, leadership, and strategic planning. Lieutenant Governor Austin Davis participated in the ceremony with a special pre-recorded message, applauding the graduates and reaffirming the Shapiro-Davis Administration's commitment to breaking down barriers for small, small diverse, and veteran-owned businesses. "Small businesses are the backbone of our communities—and when we empower them, we uplift all of Pennsylvania," Davis said. "This administration is committed to cutting red tape, reducing wait times, and creating real ladders of opportunity." League of Women Voters of Wilkes-Barre to hold Annual Meeting June 5 The League of Women Voters of Wilkes-Barre will hold its annual dinner meeting on Thursday, June 5, at 6 p.m., at Theo's Metro Restaurant, 596 Mercer Ave., Kingston. The guest speaker will be Ned Miller, the Northeast Regional Representative for Fair Districts PA. Fair Districts PA is a nonpartisan, statewide coalition that advocates redistricting reform to ensure that the process of determining Pennsylvania's congressional and state legislative districts is fair and transparent. The cost of the buffet dinner is $42 for members and $45 for non-members. RSVP by Friday, May 30. Founded in 1944, The League of Women Voters of the Wilkes-Barre Area (LWVWBA) is a nonpartisan organization that presents citizens of the Wilkes-Barre area with educational tools about issues and candidates so they can make informed decisions on election day. Activities include publishing a government directory and voters guides, voter registration drives, and hosting events where constituents can meet their elected officials. Entirely run by local volunteers, League membership is open to all, regardless of political affiliation or gender. To reserve your seat at the Annual Meeting, contact the League at — 570-675-3429 — or email at lwvwba@ Or visit the League Website at — League updates can be found on Facebook @LWVWB. Reach Bill O'Boyle at 570-991-6118 or on Twitter @TLBillOBoyle.
Business Wire
12-05-2025
- Business Wire
Genascence Phase 1b DONATELLO Trial Evaluating Potential First-in-Class Gene Therapy for Knee Osteoarthritis (OA) Meets Primary Endpoint Showing GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms
PALO ALTO, Calif.--(BUSINESS WIRE)--Genascence Corporation ('Genascence'), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced positive 12-month safety and biomarker results from the Phase 1b DONATELLO clinical trial evaluating GNSC-001, a potential first-in-class gene therapy blocking interleukin 1 (IL-1) for the treatment of knee osteoarthritis (OA). Results from the 12-month analysis showed the study met the primary endpoint, demonstrating continued safety and tolerability across all doses tested, as well as the key secondary endpoint showing sustained IL-1Ra expression in synovial fluid, building on data reported through the six-month visit. GNSC-001 is a genetic medicine – a recombinant adeno-associated viral vector expressing an optimized human interleukin-1 receptor antagonist (IL-1Ra), a naturally occurring protein that blocks IL-1 signaling. IL-1 is considered one of the key mediators involved in the pathogenesis of OA, causing inflammation, joint pain, and cartilage destruction. GNSC-001 is designed to offer long-term, sustained inhibition of IL-1 following a single intra-articular injection into the affected joint. The U.S. Food and Drug Administration (FDA) granted GNSC-001 Fast Track designation in the fourth quarter of 2024. Genascence recently completed a successful meeting with the FDA on the design of the Phase 2b/3 clinical trial of GNSC-001 focused on clinical efficacy and plans to initiate the Phase 2b/3 study in 2026. 'Osteoarthritis is incapacitating, causing years of pain and disability for people living with the disease. Current treatment options are limited to managing pain and do not treat the underlying disease itself,' said Thomas Chalberg, Ph.D., founder and CEO of Genascence. 'The 12-month safety and sustained IL-1Ra expression data affirms the promise of GNSC-001 to potentially transform the treatment paradigm for OA. We are pleased by the successful meeting with the FDA, and look forward to initiating the study, transitioning GNSC-001 to late-stage clinical development so we can bring a new treatment option to people suffering from this disabling disease.' 'GNSC-001 is the first IL-1 inhibitor that has been shown to generate IL-1Ra expression levels that reach and maintain therapeutic thresholds long-term following a single administration,' said Annahita Keravala, Ph.D., chief scientific officer (CSO) of Genascence. 'Results from the DONATELLO clinical trial suggest that our novel therapeutic approach, a local gene therapy can potentially have therapeutic benefit in knee OA, a disease for which there are no treatments beyond management of symptoms. This would be transformative for people suffering from this debilitating condition, and thus warrants further development.' "These results from the DONATELLO trial reflect the kind of innovation CIRM was created to support,' said Lisa Kadyk, Ph.D., CIRM Fellow, Clinical Development at the California Institute for Regenerative Medicine (CIRM), which supported the DONATELLO clinical trial with a $12 million award. 'By harnessing the power of gene therapy, GNSC-001 represents a novel and potentially disease-modifying approach to treating osteoarthritis. We are encouraged by the 12-month safety and biomarker data and proud to have supported this important step toward a more effective, long-term treatment for people living with knee OA." Dr. Keravala will present data from the six-month interim analysis of the DONATELLO clinical trial at the 28 th Annual American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting, being held May 13-17, 2025 in New Orleans, LA and virtually. The poster presentation details are provided below. Title: A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Phase 1b Study Evaluating Safety, Tolerability, and Pharmacodynamics of a Local AAV-Mediated Anti-Interluekin-1 Gene Therapy in Subjects with Knee Osteoarthritis: 6-Month Interim Results Date/Time: Thursday, May 15, 2025, 5:30-7:00 pm CT Location: Poster Hall Abstract Number: AMA616 Poster Number: 1849 Abstracts can be found at About the DONATELLO Clinical Trial The DONATELLO Phase 1b clinical trial (NCT05835895) is a double-blind, placebo-controlled dose-ranging study designed to evaluate the safety, tolerability, and pharmacodynamics of a single intra-articular injection of GNSC-001 in patients with OA of the knee. The study enrolled 67 participants with OA at 10 centers across the U.S. The first five groups were randomized to receive GNSC-001 at doses of 110 12 vg or 110 13 vg, with or without a short course of oral steroids for immune-conditioning, or a placebo (saline) injection. The trial was expanded to enroll an additional, non-randomized arm. In this arm, pre-treatment synovial fluid sampling was required for entry, and subjects received 110 13 vg GNSC-001 with an abbreviated three-day course of oral steroids plus a local, intra-articular steroid injection. Data and Safety Summary The primary endpoints of the DONATELLO clinical trial are safety and tolerability. Through 12 months of follow-up, data show that GNSC-001 was well tolerated, with no treatment-emergent or treatment-related deaths, serious adverse events (SAEs), or adverse event (AE)-related withdrawals reported. The most common target knee AEs included arthralgia, joint swelling, and joint effusion. The study's secondary endpoints include expression levels of interleukin-1 receptor antagonist (IL-1Ra) in synovial fluid at Month 12, as well as change from baseline to Month 12. Results revealed that mean expression of IL-1Ra reached target therapeutic levels in multiple arms of the study and remained above the target threshold throughout the 12-month follow up period. Immune-conditioning with a short course of steroids generally supported higher levels of prolonged IL-1Ra expression. The DONATELLO clinical trial was supported by a $12 million award from the California Institute for Regenerative Medicine (CLIN2-14265). About Osteoarthritis (OA) of the Knee Osteoarthritis (OA) is a progressive joint disease that is a leading cause of disability. It is characterized by destruction of cartilage and structural changes in bone within the joint, which contribute to pain and loss of joint function. Osteoarthritis affects more than 30 million Americans and is increasing as a result of the aging population and increasing prevalence of obesity. Osteoarthritis represents a major economic burden, owing to direct medical costs and loss of productivity. Each year, millions of patients are treated for knee OA with NSAIDs, opioids, and steroid injections into the knee to manage their knee pain. There are no currently available therapies known to alter or slow down OA progression. About Genascence Corporation Genascence, a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, is developing life-changing treatments for highly prevalent conditions affecting millions of people. The company was founded in 2017 with technology licensed from three leading U.S. research institutions: Mayo Clinic, University of Florida, and NYU Langone Health. Headquartered in Palo Alto, California, Genascence's founders and leadership team have deep experience in the design, development, and manufacturing of successful gene therapies and biological medicines. For more information, please visit
